Quantcast

Number of Shares in Elekta As of August 29, 2008

August 29, 2008

Regulatory News:

Elekta (STO:EKTAB):

According to legislation, all publicly listed companies must – if the number of shares has changed during the month – publish the total number of shares in the company on the last trading day of the month.

During August 79,053 new B shares were issued in Elekta through the exercise of warrants distributed within the framework of the established option program.

The total number of shares in Elekta as of August 29, 2008, amounts to 93,075,863 divided between 3,562,500 A shares and 89,434,310 B shares.

One Series A share entitles the holder to 10 votes and one Series B share to one vote.

Elekta’s current holding of own shares (treasury stock) amounts to 951,300 B shares, repurchased during January and February 2008. The Board intends to propose to the next AGM that also these shares should be cancelled.

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and information systems as well as services for improved cancer care and management of brain disorders.

Elekta’s systems and solutions are used in over 5,000 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) and Elekta Synergy(R) for stereotactic and image guided radiation therapy and radiosurgery as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.

With over 2,500 employees globally, the corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information about Elekta can be found at www.elekta.com.

This information was brought to you by Cision http://newsroom.cision.com




comments powered by Disqus